Clinical trial
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
NCT00078195 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00078195 |
|---|---|
| Title | Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies |
| Official title | Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered With Omalizumab, an Anti-IgE Monoclonal Antibody (ITN019AD) |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Immune Tolerance Network (ITN) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hay Fever, Hypersensitivity, Allergy, Rhinitis |
| Intervention type | Biological |
| Interventions | omalizumab, Placebo omalizumab, Ragweed rush immunotherapy (RIT), Placebo rush immunotherapy (RIT), Ragweed immunotherapy (IT), Placebo immunotherapy (IT) |
| Enrollment | 168 |
| Start date | Apr 1, 2003 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Feb 20, 2004 |
| Last update posted | Oct 18, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: